Vestibular neuronitis
https://doi.org/10.21518/2079-701X-2021-2-31-36
Abstract
Vestibular neuronitis occurs as a result of damage to the vestibular nerve and is manifested by a sudden and prolonged attack of vestibular vertigo, accompanied by nausea, vomiting and imbalance. Questions of etiology, pathogenesis, clinical picture, diagnosis and treatment of VN are discussed. The disease is associated with selective inflammation (viral or infectious-allergic genesis) of the vestibular nerve. The role of herpes simplex virus type 1 is confirmed by cases of herpetic encephalitis in VN. In 2020, cases of VN development in patients with COVID-19 are described. VN usually affects the upper branch of the vestibular nerve, which innervates the horizontal and anterior semicircular canals. The duration of vertigo with VN ranges from several hours to several days. The timing of the restoration of vestibular function depends on the degree of damage to the vestibular nerve, the speed of central vestibular compensation and the patient’s performance of vestibular gymnastics. Some patients, months and even years after VN, experience significant instability. The diagnosis of VL is based on the clinical picture of the disease, the results of an otoneurological examination, and the exclusion of other diseases. VN treatment is aimed at reducing dizziness, nausea and vomiting and accelerating vestibular compensation. In our country VN is rarely diagnosed, which is associated with poor awareness of doctors about this disease. The article presents the observation of a 46-year-old patient with VN, who was mistakenly diagnosed with vertebrobasilar insufficiency, which contributed to the patient’s long-term disability. Establishing the correct diagnosis, educational work with the patient, conducting vestibular gymnastics led to an improvement in the condition, regression of instability. The issues of the effectiveness of vestibular gymnastics, the use of betahistine to accelerate the recovery of patients with VN are discussed.
About the Author
V. A. Parfenov
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Vladimir A. Parfenov, Dr. of Sci. (Med.), Professor, Head of the Department of Nervous Diseases and Neurosurgery
8, Bldg. 2, Trubetskaya St., Moscow, 119991
References
1. Muncie H.L., Sirmans S.M., James E. Dizziness: Approach to Evaluation and Management. Am Fam Physician. 2017;95(3):154–162. Available at: https://aafp.org/afp/2017/0201/p154.html.
2. Parfenov V.A., Zamergrad M.V., Melnikov O.A. Dizziness: diagnosis and treatment, common diagnostic errors. 3 th ed. Moscow: MIA; 2019. 208 р. Available at: https://medknigaservis.ru/product/golovokruzhenie-diagnostika-i-lechenie-rasprostranennye-diagnosticheskie-oshibki.
3. Tarnutzer A.A., Berkowitz A.L., Robinson K.A., Hsieh Y.H., Newman-Toker D.E. Does my dizzy patient have a stroke? A systematic review of bedside diagnosis in acute vestibular syndrome. CMAJ. 2011;183(9):E571–592. doi: 10.1503/cmaj.100174.
4. Baloh R.W. Clinical practice. Vestibular neuritis. N Engl J Med. 2003;348(11):1027–1032. doi: 10.1056/NEJMcp021154.
5. Bartual-Pastor J. Vestibular neuritis: etiopathogenesis. Rev Laryngol Otol Rhinol (Bord). 2005;126(4):279–281. Available at: https://pubmed.ncbi.nlm.nih.gov/16496559.
6. Philpot S.J., Archer J.S. Herpes encephalitis preceded by ipsilateral vestibular neuronitis. J Clin Neurosci. 2005;12(8):958–959. doi: 10.1016/j.jocn.2004.11.014.
7. Malayala S.V., Raza A. A Case of COVID-19-Induced Vestibular Neuritis. Cureus. 2020;12(6):e8918. doi: 10.7759/cureus.8918.
8. Vanaparthy R., Malayala S.V., Balla M. COVID-19-Induced Vestibular Neuritis, Hemi-Facial Spasms and Raynaud’s Phenomenon: A Case Report. Cureus. 2020;12(11):e11752. doi: 10.7759/cureus.11752.
9. Halmagyi G.M., Aw S.T., Karlberg M., Curthoys I.S., Todd M.J. Inferior vestibular neuritis. Ann N Y Acad Sci. 2002;956:306–313. doi: 10.1111/j.1749-6632.2002.tb02829.x.
10. Furman J.M., Cass S.P. Benign paroxysmal positional vertigo. N Engl J Med. 1999;341(21):1590–1596. doi: 10.1056/NEJM199911183412107.
11. Staab J.P., Eckhardt-Henn A., Horii A., Jacob R., Strupp M., Brandt T., Bronstein A. Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular Disorders of the Bárány Society. J Vestib Res. 2017;27(4):191–208. doi: 10.3233/VES-170622.
12. Antonenko L.M., Zastenskaya E.N. Persistent postural-perceptual dizziness: current approaches to diagnosis and treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):136–140. (In Russ.) doi: 10.14412/2074-2711-2019-4-136-140.
13. Huppert D., Strupp M., Theil D., Glaser M., Brandt T. Low recurrence rate of vestibular neuritis: a long-term follow-up. Neurology. 2006;67(10):1870–1871. doi: 10.1212/01.wnl.0000244473.84246.76.
14. Navi B.B., Kamel H., Shah M.P., Grossman A.W., Wong C., Poisson S.N. et al. Rate and predictors of serious neurologic causes of dizziness in the emergency department. Mayo Clin Proc. 2012;87(11):1080–1088. doi: 10.1016/j.mayocp.2012.05.023.
15. Kattah J.C., Talkad A.V., Wang D.Z., Hsieh Y.H., Newman-Toker D.E. HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. Stroke. 2009;40(11):3504–3510. doi: 10.1161/STROKEAHA.109.551234.
16. Karlberg M., Annertz M., Magnusson M. Acute vestibular neuritis visualized by 3-T magnetic resonance imaging with highdose gadolinium. Arch Otolaryngol Head Neck Surg. 2004;130(2):229–232. doi: 10.1001/archotol.130.2.229.
17. Park K.M., Shin K.J., Ha S.Y., Park J.S., Kim S.E. A Case of Acute Vestibular Neuritis Visualized by Three-Dimensional FLAIR-VISTA Magnetic Resonance Imaging. Neuroophthalmology. 2014;38(2):60–61. doi: 10.3109/01658107.2013.874454.
18. Antonenko L.M., Parfenov V.A. A specialized approach to diagnosing and treating vertigo. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(1):56–60. (In Russ.) doi: 10.14412/2074-2711-2016-1-56-60.
19. Brandt T., Huppert T., Hüfner K., Zingler V.C., Dieterich M., Strupp M. Longterm course and relapses of vestibular and balance disorders. Restor Neurol Neurosci. 2010;28(1):69–82. doi: 10.3233/RNN-2010-0504.
20. Kim Y.H., Kim K.S., Kim K.J., Choi H., Choi J.S., Hwang I.K. Recurrence of vertigo in patients with vestibular neuritis. Acta Otolaryngol. 2011;131(11):11721177. doi: 10.3109/00016489.2011.593551.
21. Strupp M., Zingler V.C., Arbusow V., Niklas D., Maag K.P., Dieterich M. et al. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med. 2004;351(4):354–361. doi: 10.1056/NEJMoa033280.
22. Fishman J.M., Burgess C., Waddell A. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst Rev. 2011;(5):CD008607. doi: 10.1002/14651858.CD008607.pub2.
23. Sjögren J., Magnusson M., Tjernström F., Karlberg M. Steroids for Acute Vestibular Neuronitis – the Earlier the Treatment, the Better the Outcome? Otol Neurotol. 2019;40(3):372–374. doi: 10.1097/MAO.0000000000002106.
24. Vroomen P. Methylprednisolone, valacyclovir, or both for vestibular neuritis. N Engl J Med. 2004;351(22):2344–2345. Available at: https://pubmed.ncbi.nlm.nih.gov/15570684.
25. Della Pepa C., Guidetti G., Eandi M. Betahistine in the treatment of vertiginous syndromes: a meta-analysis. Acta Otorhinolaryngol Ital. 2006;26(4):208–215. Available at: https://pubmed.ncbi.nlm.nih.gov/18236637.
26. Nauta J.J. Meta-analysis of clinical studies with betahistine in Ménière’s disease and vestibular vertigo. Eur Arch Otorhinolaryngol. 2014;271(5):887–897. doi: 10.1007/s00405-013-2596-8.
27. Benecke H., Pérez-Garrigues H., Bin Sidek D., Uloziene I., Kuessner D., Sondag E. Theeuwes A. Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study. Int Tinnitus J. 2010;16(1):14–24. Available at: https://pubmed.ncbi.nlm.nih.gov/21609908.
28. Morozova S.V., Alekseeva N.S., Lilenko S.V., Matsnev E.I., Melnikov O.A. Effects and safety profile of betahistine in patients in the Russian contingent of OSVaLD, an open-label observational study in vestibular vertigo. Int J Gen Med. 2015;8:47–53. doi: 10.2147/IJGM.S73842.
29. Parfenov V., Golyk V., Matsnev E., Morozova S.V., Melnikov O.A., Antonenko L.M. et al. Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study. PLoS One. 2017;12(3):e0174114. doi: 10.1371/journal.pone.0174114.
30. Parfenov V.A., Zamergrad M.V., Kazei DV., Nauta Y. A study of the efficacy and safety of a new modified-release betahistine formulation in the treatment of vestibular dizziness and Meniere’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12):42–48. (In Russ.) doi: 10.17116/jnevro202012012142.
Review
For citations:
Parfenov VA. Vestibular neuronitis. Meditsinskiy sovet = Medical Council. 2021;(2):31-36. (In Russ.) https://doi.org/10.21518/2079-701X-2021-2-31-36
Views:
1771
Email this article 